Author Archives: Steve Bryson PhD

Fabrazyme Safe, Effective in Japanese Study

Fabrazyme (agalsidase beta) demonstrated an acceptable safety profile and resulted in sustained reductions in globotriaosylceramide (GL-3) levels over seven years among patients with Fabry disease, a large real-world study from in Japan found.  The study, “…